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Introduction
Prostate cancer is the most commonly diagnosed internal malignancy in men and is a leading cause of cancer death in Western society. 1 The standard therapies for localized disease, including surgical resection and radiotherapy, may be effective in specific cases, but can produce serious side-effects and a low level of mortality. 2, 3 Patients with occult or clinical metastatic disease are managed with palliative hormone therapy, as there are no documented curative therapies. Therefore, there is clearly a need for novel more effective therapies for prostate cancer. One novel therapeutic approach involves in situ gene therapy mediated by viral vectors including recombinant adenoviruses. We have previously tested this approach using adenovirus-mediated transduction of the normal p53 or p21 gene directly into p53-deficient mouse prostate cancer cells growing as subcutaneous tumors. 4 Further studies investigated the therapeutic activities of suicide gene therapy using the herpes simplex virus-thymidine kinase (HSVtk) gene followed by ganciclovir (GCV) in both subcutaneous and orthotopic mouse prostate cancer models. [5] [6] [7] The results of the HSVtk + GCV studies indicated not only local tumor growth suppression, but also systemic antimetastatic activity induced by a local injection. These preclinical studies spawned a phase I clinical trial that has produced evidence of the safety of this approach and some preliminary indications of activity. 8 Overall, the results of our preclinical and clinical studies suggest that the local and systemic activities produced by HSVtk + GCV therapy are mediated in part by an antitumor immune response. This notion is consistent with the results of other in vivo studies that indicate HSVtk + GCV therapy generates an immune response. 9, 10 More recent studies have further demonstrated that HSVtk + GCV therapy can lead to the induction of a Th1 immune response that may play a role in the observed antitumor immunity. 11, 12 Therefore, to extend our previous work towards a more direct immunomodulatory gene therapy approach, we considered in situ adenovirus-mediated IL-12 gene transduction as a therapy for prostate cancer.
Previous studies have demonstrated significant efficacy of systemic IL-12 therapy against a wide variety of tumors. 13 However, the initial clinical trials using recombinant IL-12 were fraught with severe IL-12-related toxicity.
14 Although clinical testing of systemic IL-12 therapy has subsequently resumed, alternative approaches, including gene therapy, for the delivery of IL-12 have been pursued. These include injection of genetically engineered fibroblasts for the secretion of IL-12 in an orthotopic melanoma model; direct transfer of IL-12 cDNA via gene gun-mediated transfection of skin tissue overlaying subcutaneous melanomas; direct intratumoral injection of adenovirus expressing IL-12 in ectopic breast and colon cancer models; and intradermal injection of IL-12 cDNA and vaccination using irradiated IL-12-transfected tumor cells in a metastatic colon cancer model. [15] [16] [17] [18] [19] [20] [21] These models suggest that IL-12 gene therapy results in tumor regression and suppression of metastasis.
In this article, we show for the first time in experimental prostate cancer that a single intratumoral injection of a recombinant adenovirus expressing murine IL-12 (AdmIL-12) resulted in suppression of tumor growth, enhanced survival compared with controls and suppression of pre-established lung metastasis. We further document that this therapy generates elevated systemic natural killer (NK) cell-mediated cytolysis and nitric oxide synthase (NOS) activity within the AdmIL-12-treated tumor. Extensive infiltration of macrophages and T cells within treated tumors was also documented.
Results

Characterization of RM-9 cells
To determine the ability of RM-9 cells to express MHC class I antigen compared with other RM cell lines derived from the MPR model for prostate cancer, 22, 23 flow cytometric analysis with immunofluorescence detection of class I major histocompatibility (MHC) antigen expression was performed (Table 1) . RM-9 cells had lower mean fluorescent intensity (MFI) and fewer positive cells than RM-1 or RM-2. Stimulation by interferon-␥ (IFN) resulted in up-regulation of MHC class I in all RM cell lines analyzed, however to a much smaller extent in the RM-9 cells.
In vitro IL-12 gene transduction RM-9 cells were infected with AdmIL-12 in vitro to determine if cell proliferation was affected by AdmIL-12 infection, and to measure the level of IL-12 production. At 24 and 48 h following viral infection, there was no significant difference in cell number per well at any MOI compared to control wells (MOI of 0) (Figure 1a ). The ability of the vector to express mIL-12 was determined by ELISA on supernatants harvested from the wells at 24 and 48 h. A time-and dose-dependent production of mIL-12 was observed ( Figure 1b) .
In situ IL-12 gene therapy suppresses local growth A dose-escalation experiment was performed to determine a target therapeutic viral dose and the most efficacious titer of AdmIL-12. Orthotopic tumors with RM-9 cells were injected with increasing doses of AdmIL-12 in a volume of 25 l 7 to 8 days after cell inoculation. Both the 1 × 10 8 and the 3 × 10 8 p.f.u. doses of AdmIL-12 (1359 and 1392 mg, repectively) demonstrated significant and comparable growth suppression of tumors after an additional 14 days (P Ͻ 0.001) with tumor wet weights that were over 50% smaller than either PBS (2933 mg) or ADV/CMV/␤gal (3227 mg) injected tumors. Doses of 5 × 10 7 gave intermediate growth suppression (2240 mg, P = 0.02) (Figure 2 In situ IL-12 gene therapy increases survival Mean survival for the control group injected with Adv/CMV/␤gal (n = 36) was 23.4 ± 0.8 days, while in the AdmIL-12 treatment group (n = 38) the mean survival was 28.9 ± 1.2 days. Figure 3 presents a cumulative Kaplan-Meier survival plot for each of the groups of animals. There was a statistically significant (P Ͻ 0.0001) dif- and adapted for in vitro culture conditions, 23 carcinomas produced by RM-9 cells are metastatic to lymph nodes following orthotopic injection. In the AdmIL-12 dose response experiment, histology of regional pelvic lymph nodes with H&E staining showed a reduction in the number of nodes with spontaneous metastases compared with the control group. This was confirmed by cytokeratin staining. In the IL-12 treated groups 50% of mice (n = 22) showed evidence of nodal metastases, while metastases were seen in 83% of the control animals (n = 6) ( Figure 4a ).
To test for IL-12 gene therapy activity against preestablished metastases, two protocols were evaluated. In a low metastasis protocol lung metastases were established by injection of 50 000 RM-9 cells in a volume of 100 l via the tail vein of each animal, at the same time as orthotopic injection of 5000 RM-9 cells. In a high metastasis protocol 100 000 cells were injected via the tail vein at the same time as orthotopic injection of 5000 cells. The low metastasis protocol generated experimental lung metastases detectable as macroscopic lesions (mean, 3.0 ± 1.0 metastases, n = 4) on day 6, the time of vector treatment of the orthotopic tumor. At 14 days after tail vein and orthotopic cell inoculation (8 days after intraprostatic virus injection), counts of gross lung metastases in the mice that received the intraprostatic AdmIL-12 injection revealed a reduction in the number of lung metastases compared with controls, however this did not quite achieve statistical significance (P = 0.056) (Figure 4b ). On examination by dissecting microscope, the size of the metastases in both groups appeared equal. In the high metastasis protocol (Figure 4b ) the number of lung metastases was increased to 62.0 ± 3.0 in the control group with Adv/CMV/␤gal-treated orthotopic tumors, as compared to only 16 ± 6.1 in the low metastasis protocol. AdmIL-12 treatment of the orthotopic tumors in animals in the high metastasis protocol led to a significant reduction in pre-established lung metastases, 23.9 ± 4.6 (P = 0.017).
Kinetic analysis of treatment activities
Following intraprostatic injection of AdmIL-12 tumor weight was monitored at each time-point ( Figure 5a) . A significant suppression of tumor weight was observed in the IL-12-treated group compared with the controls. Tumor growth gradually increased towards the end of the experiment, and became more rapid after day 10 following virus injection. Serum IL-12 levels were maximal at day 1 after treatment (15.2 ng/ml), and decreased to 1.78 ng/ml by 3 days after injection. The levels were undetectable at 14 days after virus injection. In control groups, IL-12 was either undetectable or detected at minimal levels (less than 0.5 ng/ml at day 1 and day 7 in the ADV/CMV/␤-gal group) ( Figure 5b ).
Spleen size was monitored at all time-points ( Figure  5c ). At day 0 the average spleen weight was 85 mg. In the IL-12-treated group the spleen weight increased during the experiment to a maximum of 435 mg at day 7, after which it decreased again to 163 mg at day 14. In the control groups, a similar pattern was observed, but the maximum spleen size on day 7 was 143 mg, and at day 14 the weight was 53 mg.
NK cell cytolytic and CTL activities in splenocytes NK cell activity of splenocytes was increased during the first 7 days after AdmIL-12 injection with a maximum lysis of 25.3% (E:T = 50:1). This was detected on the first day after virus injection, and returned to baseline activity over the next 7 days (Figure 6 ). RM-9 specific CTL activity in spleen-derived T cells was not detected at day 14.
CD8/CD4 ratios in splenocyte-derived lymphocytes The number of CD8 + to CD4 + lymphocytes in the spleens of animals was determined by flow cytometric analysis and the ratio of CD8 + to CD4 + cells calculated. A peak of increased CD8/CD4 ratio occurred around day 3 in all groups but the increase was most dramatic in the AdmIL-12 treated animals ( Figure 7 ).
Nitric oxide synthase activity in the orthotopic tumor Total nitric oxide synthase activity was increased 1.5-to two-fold in tissue extracts of IL-12-treated tumors compared with tissue extracts from control tumors when measured 1 day after virus injection and remained elevated for 10 days (Figure 8 ).
Quantitative immunohistochemical analysis during the course of treatment
The relative numbers of F4/80-positive cells, iNOS positive cells as well as CD4
+ and CD8 + T cells, in orthotopic prostate tumors 1-2, 5, 7 and 14 days following injection with AdmIL-12 or control vectors were determined using quantitative immunohistochemistry. Representative specimens for selected time-points from IL-12 treatment groups and controls are shown in Figure 9 and the results of quantitative analysis are shown in Figure 10 .
A highly significant infiltration of F4/80-positive cells was observed at days 1-2 in IL-12-treated tumors relative to controls (Figures 9a and b, and 10a) . Infiltrating F4/80-positive cells in IL-12-treated tumors had decreased rapidly in number by day 7 and were approximately equivalent to controls by day 14. Interestingly a significant increase in iNOS-positive cells with distinct macrophage morphology was observed at day 7 following IL-12 gene therapy relative to controls (Figure 9c and d, and Figure  10b ). As the level of iNOS-positive cells is substantially lower than the number of F4/80-positive cells at this time, it appears that activated macrophages represent only a fraction of the F4/80-positive cell population. By day 14, iNOS-positive cells are reduced in number in IL-12-treated tumors and approach, but do not achieve, control levels. A similar pattern of IL-12 stimulation was also observed for infiltration of CD4 + and CD8 + T cells. Significantly increased numbers of these two T cell populations were observed at day 7, their numbers decreased by day 14 following IL-12 gene therapy (see Figure 9e -h and Figure 10c ).
Effects of inhibition of NK activity
Systemic injection of three mice with anti-asialo-GM1 serum reduced the activity of splenocyte-derived NK cells isolated 2 days following AdmIL-12 treatment of orthotopic RM-9 tumors to an average of 6.0% lysis at E:T of 50 compared with an average of 27.7% lysis in animals which were not injected with anti-asialo-GM1 serum (Figure 11a ). Animals with ADV/CMV/␤-gal treated tumors pretreated with intraperitoneal antiasialo-GM1 serum had only background levels NK activity (Ͻ10%) in splenocytes and one animal that did not receive anti-asialo-GM1 serum had low levels consistent with those demonstrated previously (see Figure 6 ). These results show that the anti-asialo GM1 treatment was effective at depleting and blocking IL-12-induced NK activity. NK activity was not detectable in splenocytes from mice 8 days after AdmIL-12 or ADV/CMV/␤-gal virus injection either with or without anti-asialo-GM1 serum treatment. The biological effects of blocking NK activity with antiasialo-GM1 serum were evaluated 8 days after virus injection by measuring orthotopic tumor volume ( Figure  11b ) and number of pre-established lung metastases 
Discussion
In the present study we demonstrated that a single orthotopic injection of AdmIL-12 significantly suppresses tumor growth and increases the survival time in mice with established murine prostate tumors. Activation of an antitumoral immune response was extensively documented. Further, suppression of pre-established metastases was observed. For this study, we used the RM-9 orthotopic prostate cancer model system to test the antitumoral and antimetastatic activity of IL-12 gene therapy. Previously we used the RM-1 and RM-2 cell lines in cytotoxic gene therapy experiments with adenovirusmediated thymidine kinase gene therapy. [5] [6] [7] In this article, we introduced the RM-9 cell line, which forms relatively higher numbers of spontaneous regional metastases, but grows more slowly orthotopically, allowing for a longer follow-up time. Although constitutive expression of the MHC class I antigens is reduced in the RM prostate cancer cell lines, MHC class I expression can be increased by stimulation with IFN-␥. Of the RM cell lines tested, RM-9 appears to have the lowest level of MHC class I induction. This MHC class I profile is highly analogous to that of multiple human prostate cancer cell lines 24 further validating its use as a model system for immunomodulatory gene therapy protocols. The orthotopic model is a preferred model for the analysis of immunogenic activities within a realistic micro-environment that includes prostatic stromal cells. In contrast to orthotopic models, subcutaneous tumors may induce a high inherent immunogenicity due to the presence of antigen-presenting cells like dendritic cells. As previously suggested by Sampson et al, 25 we also speculate that, like the central nervous system, the prostate represents a less permissive environment, compared with the skin, for the development of an effective antitumoral immune response. Thus successful generation of antitumoral immunity against subcutaneous tumors does not necessarily indicate the same efficacy against tumors in an orthotopic site. We and others have found these arguments sufficiently compelling to use orthotopic prostate cancer models whenever possible for preclinical studies especially those that involve the generation of an immune response. 6, 26 Immunostimulatory activities of IL-12, such as NK cell activation and generation of specific antitumoral immunity, have been demonstrated in several model systems. [13] [14] [15] [16] [17] [18] 21, 27 However, this is the first study showing IL-12-induced antitumoral activity or a demonstration of IL-12-generated immunostimulatory activities in experimental prostate cancer.
In the RM-9 model, IL-12-induced antitumoral activities likely result to a large extent from: (1) enhanced NK lysis activity during the first 7 days after virus injection; (2) enhanced macrophage activities such as NOS activation; and (3) supportive cytokine production and possible cytolytic activities of CD4 + and/or CD8 + T cells in tumor tissue. IL-12 can directly activate NK cells via specific surface receptors. This leads to the production of IFN-␥ by NK cells, and increased cytotoxic activity of NK cells against tumor cells with low MHC class I expression. 28, 29 The cytotoxic activity may be the result of perforin-mediated lysis independent of the production of IFN-␥. 30 In the present study, increased NK activity was documented by YAC cell lysis assays with splenocytes with a maximum on day 1 and persistence to day 3 after IL-12 gene therapy. This activity was inhibited by pretreatment of the mice with antibody known to block NK cells, anti-asialo-GM1. 31, 32 Although our study indicates that a minimal increase in systemic NK activity can result from adenovirus infection per se (ie vector control group) it is apparent that the induction of NK activity by IL-12 far exceeds this nonspecific virus effect (Figures 6 and  11) .
Recent studies concerning the relationship between IL-12 efficacy and NK cell versus CTL cell killing may explain in part the initial rise and subsequent decline in NK cell activity, and the later increase in CD8
+ cell infiltration that we observed in our study. IL-12 has been reported to induce a NK-mediated cytolytic phase followed later by a T cell phase that is characterized by CTL activities. 27 Although the interrelationships between the NK phase and the CTL phase are poorly understood, it appears that the generation of a Th1 response is required for the CTL phase. We observed increased infiltration of both CD4
+ and CD8 + T cells 7 days after virus injection and 6 days following maximum NK activity at day 1 after virus injection. However, the intratumoral CD4 + and CD8
+ T cell population subsequently decreased to nearly control levels 14 days following IL-12 treatment. Thus, a supportive Th1 response may not have developed. This may explain in part our inability to demonstrate CTL activity 14 days after AdmIL-12 injection. Interestingly, it was recently reported that a 2-week period of impaired immune effector activities were produced in mice vaccinated with rmIL-12, resulting in a transient period of negative CTL assays. 33 Since NK depletion did not completely eliminate the IL-12 anti-metastatic activity it appears that other mechanisms may in part be responsible including other lineages of lymphoid-derived cells. Other cells distinct from NK and T cells have been identified as being involved in the antitumor response following IL-12 treatment. V ␣ 14 NKT cells have been shown to be a distinct population of NK-like effector cells induced by systemic IL-12. These cytolytic cells can effect a reduction in metastasis to the liver of erytholeukemia or B16 melanoma cells and reduced lung metastases from B16 melanoma or Lewis lung carcinoma cells. 34 A similar IL-12-inducible lineage called NK1.1
+ TCR int cells has been reported to be the primary effector cell against hepatic and lung metastases. 35 In addition to NK and CTL cytokine activities, nitric oxide has been reported to play an important role in the antitumor activities of IL-12. Wigginton et al 36 reported that IL-12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages in tumor-bearing mice. The expression of the inducible isoform of nitric oxidase synthase is also directly stimulated by IFN-␥. 37 In the present study, we not only showed an increased presence of cells positively stained iNOS, we also showed increased total activity of NOS in tumor tissue treated with AdmIL-12 compared with control tumors. These data further support a role for macrophage-derived nitric oxide as an antitumor effector that is stimulated indirectly by IL-12.
It is of importance that antimetastatic activity of a single AdmIL-12 treatment was demonstrated by the reduction in the number of spontaneous regional lymph node metastases and established lung metastases. This extends the observations made by others in different tumor models and also underscores the systemic effects of orthotopic AdmIL-12 treatment. Our results further indicate that a significant component of this antimetastatic effect of IL-12 is mediated by NK activities that may include direct cytolysis and/or secretion of IFN-␥. 38 A non-NK component of the antimetastatic effect was also evident. Further studies that address the antimetastatic effects of IL-12 gene therapy are indicated.
Few studies have reported on the toxicity of IL-12 gene therapy, though the systemic administration of IL-12 in humans lead previously to a life-threatening myelosuppression and splenomegaly.
14 In the present study, serum levels after the orthotopic injection of AdmIL-12 showed an obvious dose relationship. Serum concentrations of IL-12 were increased during a period of 10 days after initiation of the treatment and maximal on the first day. This led to enlargement of the spleen after a lag time of several days, as the maximum spleen size observed was on day 7. This splenomegaly was reversible, since the gradual decrease of the serum IL-12 strongly correlated with a return to normal spleen size. These observations are of importance for future application of IL-12 gene therapy treatments for human malignancies.
Using the RM-9 murine model for prostate we clearly demonstrated significant antitumor and systemic antimetastatic activities of a single in situ injection of IL-12. It should be appreciated that the single application of AdmIL-12 is advantageous as antitumoral therapy, but that the effects on tumor size and survival appear to be of limited duration. We are presently attempting to enhance the therapeutic effects of this therapy through modifications of the dosing schedule and with IL-12-based tumor vaccines.
Materials and methods
Mouse prostate cancer cell lines
The mouse prostate cancer cell lines, RM-1, RM-2 and RM-9, were derived from independent primary prostate tumors induced in the Zipras/myc-9-infected mouse prostate reconstitution (MPR) model system using C57BL/6 mice as previously described. 22, 23 Cells were grown in DMEM with 10% fetal bovine serum, 10 mm HEPES, penicillin (100 U/ml) and streptomycin (100 mg/ml), passaged by trypsinization with 0.025% trypsin, and maintained with routine media changes. All chemicals for cell culture were obtained from Gibco (Gaithersburg, MD, USA).
Adenoviral vectors
An adenoviral vector expressing mouse IL-12 (AdmIL-12) 39 was provided by Dr Frank Graham. In this virus, the expression cassette for the p35 subunit of IL-12 is inserted in the E1 region and the p40 subunit cassette in the E3 region. Expression of each IL-12 cDNA is driven by human cytomegalovirus (CMV) immediate-early gene promoter, and terminated by the polyadenylation signal of SV 40. The recombinant adenoviruses were isolated from a single plaque, expanded in a 293 cell line and purified by double cesium gradient ultracentrifugation. Virus titers were determined by plaque assay in 293 cells and reported as p.f.u. As a control virus vector, Adv/CMV/␤gal 40 was prepared as previously described. 5 In vitro IL-12 gene transduction To test AdmIL-12 of RM-9 cells in vitro, duplicate aliquots of 2 × 10 4 RM-9 cells were plated in serum-free medium (DMEM, 10 mm HEPES, 100 U/ml penicillin, 5 g/ml streptomycin, 0.1% bovine serum albumin) and transduced with increasing MOI. The cell numbers were determined at 24 and 48 h following transduction. Media was sampled from each of the wells at 24 and 48 h and mIL-12 assayed by enzyme-linked immunosorbent assay kits (BioSource, Camarillo, CA, USA).
Orthotopic tumor induction and establishment of preexisting lung metastases Following trypsinization, RM-9 cells were counted and re-suspended in Hank's balanced saline solution (HBSS). For orthotopic tumor inoculation syngeneic C57/BL6 mice were anesthetized with sodium pentobarbital. A low transverse abdominal incision was made and the dorso-lateral prostate was exposed. Injection of 5000 cells in 10 l directly into the right or left lobe of the dorsolateral prostate resulted in efficient and reproducible orthotopic tumor formation. A model of pre-existing lung metastases was developed in which mice received a tail vein injection (50 000 or 100 000 cells in 100 l HBSS) to induce lung metastases at the same time as the orthotopic inoculation. On day 6 or 7 after inoculation animals were randomized to receive in situ orthotopic tumor injections of either AdmIL-12 or a control 5 × 10 8 p.f.u. of Adv/CMV/␤gal. Therefore, the lung lesions had 6 days to develop before to vector injection.
In vivo IL-12 gene therapy
To determine a target therapeutic viral dose, escalating viral doses from 5 × 10 7 to 3 × 10 8 p.f.u. of AdmIL-12 were directly injected into established prostate tumors at a time (7 to 8 days after tumor cell inoculation) when the volume was approximately 5-15 mm 3 . Adv/CMV/␤gal was used as a control vector at 5 × 10 8 p.f.u. The first abdominal incision was reopened and after visualizing the prostate, a needle was placed through an intracapsular transprostatic tract before tumor penetration to minimize leakage of virus at the time of needle withdrawal. The needle point was then moved around within the tumor during injection to maximize the area exposed to the vector. Animals were killed on the 14th day after virus injection or at seven different time-points in a kinetic analysis (1, 2, 3, 5, 7, 10 and 14 days after viral injection). For survival analysis, animals were evaluated at death, or they were killed when in distress, as shown by lethargy, ruffled fur or weight loss. Sample size was 5-10 mice per treatment group except in the kinetic analysis which was six mice per time-point (three AdmIL-12, and three controls (two Adv/CMV/␤gal and one PBS)). All animals underwent a careful necropsy for gross metastasis. The primary tumor and spleen were removed and weighed. The spleen was placed in sterile media until the splenocytes could be harvested in order to perform NK and cytolytic T lymphoyte (CTL) activity assays. In addition the pelvic and retroperitoneal lymph nodes and samples of lung were excised regardless of gross appearance and along with a portion of the primary tumor processed for histological analysis. All tissues were placed in formalin, paraffin embedded, cut into 4-5-m sections and stained with hematoxylin and eosin (H&E) for histologic examination. Tissues were also frozen in OCT compound, cut into 4-5-m sections and fixed with acetone for further immunohistochemical staining. Animals with pre-existing metastases were killed on the eighth day after virus injection at which time the lungs were weighed and visible lung metastases counted with the aid of a dissecting microscope.
To block NK activity, mice were injected with 5000 RM-9 cells orthotopically and 100 000 cells via tail vein. Five days later one group received an intraperitoneal injection of 100 g of anti-asialo-GM1 serum 31, 32 in 0.15 ml. One day later the mice were operated on and the prostatic tumor injected with either AdmIL-12 or Adv/CMV/␤gal virus. Two days later, half of the animals were killed to determine tumor wet weight after careful dissection from remaining prostatic tissue, number of lung metastases visible with a dissecting microscope and NK activity in splenocytes as described above. The rest of the mice received an additional injection of anti-asialo-GM1 serum at day 3 and 6 after virus injection and were then killed on day 8 after virus injection and evaluated as above. When mice were injected with normal mouse IgG following the same timing protocol as described for the anti-asialo-GM1 serum no effect on IL-12-mediated antitumor or antimetastatic activity was observed (not shown). Previous studies have demonstrated that in vivo injections of normal serum has no effect on NK activity 31 or tumor take. 32 All mice were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and all animal studies conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Flow cytometry
Cell suspensions of 0.5-1.0 × 10 6 RM-1, RM-2 and RM-9 prostate cancer cells were stained for MHC class I antigen without or with pretreatment with interferon ␥ (IFN-␥) at 100 U/ml for 2 days. Cells were incubated with biotinconjugated anti-mouse MHC class I antibody (PharMingen, San Diego, CA, USA) then with fluorescein-conjugated avidin (Pierce, Rockford, IL, USA) for 30 min on ice, and after washing the cells were analyzed on EPICS XL-MCL (Coulter Electronics, Westbrook, ME, USA). Mean fluorescence intensity (MFI) and percent positive cells were used to compare between cell lines. Cell suspensions of 0.5-1.0 × 10 6 splenocytes were incubated with 1 g of phycoerythrin or fluorescein-conjugated antibodies to CD4 and CD8 (Pharmingen).
Cytokine assay ELISA Blood was drawn from inferior vena cava, allowed to clot and the serum was collected following centrifugation. Serum or tissue culture supernatant media was stored at −80°C until the level of IL-12 was quantitatively determined with commercially available kit (BioSource).
In vitro cytolytic assays NK cells were detected by cytolysis of 51 Cr-labeled YAC cells by splenocytes obtained from tumor-bearing mice using standard assays. 41 The Cr-labeled, interferon (IFN-␥)-stimulated RM-9 cells by splenocyte-derived T lymphocytes. Effector cells were generated by incubating spleen cells from RM-9 tumor bearing mice (9 × 10 6 cells per well) with mitomycin C-treated RM-9 cells (6 × 10 5 cells per well) in 24-well plates for 5-6 days. Anti-TGF␤ antibody (30 g/ml) was also added to the culture. Target RM-9 tumor cells were incubated with 100 U/ml IFN-␥ for 2 days and then radiolabeled with 100 Ci
51
Cr for 1 h at 37°C. Supernatants were harvested and counted in a gamma counter. The percentage of specific lysis was calculated as above.
Quantitative immunohistochemical analysis
Orthotopic prostate tumors were snap frozen with liquid nitrogen in Tissue-Tec OCT compound. They were then sectioned as 4-m slices on to polysine-coated slides and fixed in cold acetone. Immunohistochemical staining was performed using the avidin-biotin-peroxidase Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). Primary antibodies were anti-CD4 (clone:H129.19), anti-CD8 (clone:53-6.7) (PharMingen). Rat-antimouse F4/80 antigen (Clone C1:A3-1; Serotec, Oxford, UK), which recognizes the mouse F4/80 antigen expressed mainly by macrophages and the polyclonal rabbit antiinducible nitric oxide synthase antibody (Calbiochem, San Diego, CA, USA). Secondary antibodies were biotinylated goat anti-rat immunoglobulin (Vector Laboratories) and goat anti-rabbit immunoglobulin (Vector Laboratories). Sections were developed with 3,3Ј-diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO, USA) and H 2 O 2 , counterstained with methylgreen and permanently mounted. Sections were scored in a blinded manner. Computer-assisted image analysis was used to generate the number of immunopositive cells per mm 2 essentially as described previously. 42 Detection of total nitric oxide synthase activity Total nitric oxidase synthase activity in prostate tumor tissue extracts, made from approximately 20 mg fresh frozen tissue of each tumor sample, was assayed by monitoring the conversion of 3 H-arginine to 3 H-citrulline in the presence of ionized calcium (NOS assay kit; Calbiochem). The NOS activity was expressed as c.p.m. 3 H-citrulline relative to protein in the extracts as determined after conversion with dye by spectrophotometry at 595 nm (Bio-Rad, Richmond, CA, USA).
Statistical analysis
Analysis of variance (ANOVA) was used to make comparisons between the mean value of tumor weights. Kaplan-Meier survival analyses were compared with log-rank test (Mantel-Cox test). All analyses were performed with Statview 4.02 (Abacus Concepts, Berkeley, CA, USA).
